Released Nov 4, 2024, after the close
10-Q filed Nov 4, 2024, 35 days after period end · 0001628280-24-045006
Q3 2024 · 10-Q
Revenue$7.81M$7.81M −55.3% vs Q3 2023+13.4% vs Q2 2024
Net Income-$19.12M-$19.12M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.31-$0.31 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$23,852,000N/M
Operating Cash Flowderived-$21,005,000N/M
Free Cash Flowderived-$21,314,000N/M
Margins · derived
Operating margin-305.5%−207.8 pt vs Q3 2023
Net margin-244.9%−162.8 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $7.81M | $17.48M | $6.63M | $41.00K |
| Net Income | -$19.12M | -$14.35M | -$25.77M | -$26.08M |
| EPS Diluted | -$0.31 | -$0.34 | -$0.62 | -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR